Although early days, the addition of Vactosertib has resulted in 1/3 CR rate (33%).
This probably says a lot more about Vactosertib than it does CORE-NK. The combination of this drug with Pomalidomide resulted in an increase in the 6 month progression free survival of multiple myeloma patients from 20% to 80%.
This looks to be the standard PH play (IMU) of picking up mediocre assets for cheap, and attempting to find a combination treatment to make the asset commercially viable - all the while rewarding yourself handsomely to the detriment of retail holders.
CHM Price at posting:
1.4¢ Sentiment: Sell Disclosure: Not Held
